Comparative Pharmacology
Head-to-head clinical analysis: ERYMAX versus PEDIAMYCIN 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYMAX versus PEDIAMYCIN 400.
ERYMAX vs PEDIAMYCIN 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis. It also acts as a motilin receptor agonist, stimulating gastrointestinal motility.
Erythromycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking the translocation step.
250-500 mg orally every 6 hours or 500-1000 mg intravenously every 6 hours.
400 mg orally every 6 hours for 10 days.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours in adults; prolonged to 4–6 hours in hepatic impairment; requires dosing adjustment in cirrhosis.
1.5-2 hours; prolonged in renal impairment (up to 6 hours)
Renal excretion of unchanged drug: 10–15%; biliary/fecal excretion: 85–90% as active metabolites.
Renal (80-90% unchanged); biliary/fecal (minor, <5%)
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic